Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

Part B will also cover IVIG that’s administered in a hospital, outpatient clinic, or infusion center. Depending on the condition being treated, Part B may cover both the medication and the cost ...

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

This latter effect is important both because therapy in CIDP is usually episodic and because IVIg is typically a more expensive treatment and indefinite monthly infusions would be quite resource ...

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

Aim: To report the interesting case of a patient with common variable immune deficiency disease who demonstrated varied responses to intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig ...

Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY®. In case of hypersensitivity, discontinue infusion immediately and institute ...